A case of decreased hemoglobin due to upadacitinib extended-release tablets
10.12173/j.issn.1005-0698.202507025
- VernacularTitle:乌帕替尼缓释片致血红蛋白降低1例
- Author:
Cuilin XU
1
;
Naizhong HU
;
Yanyan WANG
Author Information
1. 亳州市中医院药学科(安徽亳州 236800);安徽医科大学第一附属医院药剂科(合肥 230000)
- Publication Type:Journal Article
- Keywords:
Upadacitinib;
Crohn's disease;
Decreased hemoglobin;
Adverse drug reactions
- From:
Chinese Journal of Pharmacoepidemiology
2025;34(10):1219-1223
- CountryChina
- Language:Chinese
-
Abstract:
This article reports a case of a patient with Crohn's disease who had 1 to 2 loose stools per day,occasionally with a small amount of bloody stool.Despite treatment with multiple drugs in the past,the disease was still poorly controlled.The patient was switched to upadacitinib extended-release tablets 45 mg once daily for oral administration.The patient's hemoglobin level decreased continuously,with the lowest value of 68 g·L-1.After evaluation,it was determined that the decrease in hemoglobin was very likely related to upadacitinib extended-release tablets.The upadacitinib was discontinued,and vedolizumab was used for continued treatment.Symptomatic treatment was also given,and the patient's hemoglobin level gradually recovered.This article analyzes the clinical characteristics of upadacitinib-induced hemoglobin reduction in this case and the treatment plan optimization process,to provide a reference for safe clinical medication.
